2 COVID Stocks I'd Consider Instead of Moderna

Shares of vaccine maker Moderna hit highs of nearly $500 earlier this year. But they likely aren't getting back to those heights anytime soon. And even at the stock's current price of around $330, many analysts see it as overvalued -- most price targets are no higher than $250.

No doubt, Moderna has been an exceptional investment over the past year, soaring 350% while the S&P 500 has risen by just 29%. But the gravy train for investors may be coming to an end, especially as more vaccines and options for treating COVID-19 become available. Two stocks I'd buy instead of Moderna are AstraZeneca (NASDAQ: AZN) and Merck (NYSE: MRK).

Image source: Getty Images.

Continue reading

Source Fool.com